Polycystic Ovary Syndrome (PCOS)

Polycystic ovary syndrome (PCOS) is a common endocrine and reproductive disorder characterized by varying combinations of ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology. The syndrome reflects interactions among the ovaries, hypothalamic-pituitary system, adrenal glands, adipose tissue, and metabolic pathways involved in insulin action.

Despite its name, PCOS is not simply a disorder involving ovarian cysts. The characteristic structures seen within many polycystic ovaries are predominantly developing follicles that have not progressed normally to dominant follicle selection and ovulation. Furthermore, polycystic ovarian morphology is not required in every affected individual, depending on the diagnostic criteria being applied.

PCOS can affect menstrual cyclicity, fertility, androgen-dependent tissues, and long-term metabolic health. Its manifestations vary considerably among individuals, reflecting differences in androgen production, insulin sensitivity, body composition, ovarian function, and other factors.

Ovarian Anatomy

The ovaries are paired female gonads located within the pelvic cavity. They contain germ cells and endocrine cells responsible for production of reproductive hormones.

The ovarian cortex contains follicles at different stages of development, while the medulla contains connective tissue, blood vessels, lymphatics, and nerves.

Ovarian Follicles

An ovarian follicle consists of an oocyte surrounded by specialized supporting cells that change as the follicle develops.

Follicular development progresses through several stages before a mature dominant follicle becomes capable of ovulation.

Follicular Development

The major stages of follicular development include:

• Primordial follicle
• Primary follicle
• Secondary or preantral follicle
• Antral follicle
• Preovulatory dominant follicle

Most developing follicles undergo atresia rather than completing the entire developmental sequence.

Granulosa Cells

Granulosa cells surround the developing oocyte and perform important endocrine functions.

Under stimulation from follicle-stimulating hormone (FSH), granulosa cells express aromatase and convert androgen precursors into estrogens.

Theca Cells

Theca interna cells surround the granulosa cell compartment of developing follicles.

They respond primarily to luteinizing hormone (LH) and synthesize androgen precursors that can subsequently be converted into estrogens by granulosa cells.

Two-Cell, Two-Gonadotropin Model

Normal ovarian steroidogenesis depends on coordinated activity of theca and granulosa cells.

Cell Type	Major Gonadotropin	Major Endocrine Role
Theca interna cell	LH	Produces androgen precursors
Granulosa cell	FSH	Converts androgens to estrogens through aromatase activity

Hypothalamic-Pituitary-Ovarian Axis

Ovarian activity is regulated through the hypothalamic-pituitary-ovarian (HPO) axis.

The hypothalamus releases gonadotropin-releasing hormone (GnRH), which stimulates secretion of LH and FSH from gonadotroph cells of the anterior pituitary.

Normal HPO Axis

The pathway can be summarized as:

Hypothalamus → GnRH → Anterior pituitary → LH and FSH → Ovaries

Ovarian steroid hormones and peptide hormones provide feedback to the hypothalamus and pituitary.

Gonadotropin-Releasing Hormone

GnRH is secreted in pulses rather than continuously.

The frequency and amplitude of GnRH pulses influence gonadotropin secretion and contribute to regulation of ovarian function.

Luteinizing Hormone

LH stimulates ovarian theca cells and promotes androgen synthesis.

During a normal ovulatory cycle, a midcycle LH surge is also essential for ovulation and subsequent formation of the corpus luteum.

Follicle-Stimulating Hormone

FSH supports granulosa cell proliferation, follicular development, and aromatase activity.

Appropriate FSH activity is necessary for selection and maturation of a dominant follicle.

Endocrine Dysfunction in PCOS

PCOS does not result from a single endocrine abnormality. Instead, several interacting mechanisms can contribute to the syndrome.

Important components include:

• Excess ovarian androgen production
• Altered gonadotropin secretion
• Disordered follicular maturation
• Insulin resistance in many patients
• Compensatory hyperinsulinemia
• Altered sex hormone-binding globulin concentrations

Hyperandrogenism

Hyperandrogenism is a central feature of PCOS in many affected individuals.

It may be identified clinically through androgen-dependent manifestations or biochemically through elevated circulating androgen concentrations.

Ovarian Androgen Production

The ovaries are an important source of androgen excess in PCOS.

Increased steroidogenic activity within ovarian theca cells contributes to excessive production of androgens such as testosterone and androstenedione.

Role of LH

LH stimulates androgen production by ovarian theca cells.

Alterations in hypothalamic-pituitary signaling can favor increased LH stimulation in some individuals with PCOS, although an elevated LH concentration or LH-to-FSH ratio is not required for diagnosis.

Adrenal Androgens

The adrenal cortex also produces androgen precursors.

Adrenal androgen production can contribute to biochemical androgen excess in some individuals with PCOS, although ovarian androgen excess is a major component of the syndrome.

Insulin Resistance

Insulin resistance is common in PCOS and can occur independently of obesity.

It refers to reduced responsiveness of target tissues to the metabolic actions of insulin, requiring greater insulin secretion to maintain glucose homeostasis.

Hyperinsulinemia

When pancreatic beta cells compensate for insulin resistance by increasing insulin secretion, circulating insulin concentrations rise.

This compensatory hyperinsulinemia can interact directly with ovarian steroidogenesis.

Insulin and Ovarian Androgen Production

Insulin can enhance androgen production within ovarian theca cells and can act together with LH to promote steroidogenesis.

Hyperinsulinemia therefore provides an important link between metabolic dysfunction and reproductive endocrine abnormalities in PCOS.

Sex Hormone-Binding Globulin

Sex hormone-binding globulin (SHBG) is produced primarily by the liver and binds circulating sex steroids.

Hyperinsulinemia can suppress hepatic SHBG production, increasing the proportion of circulating testosterone that is unbound or biologically available.

Insulin-Androgen Interaction

Abnormality	Potential Effect
Insulin resistance	Increases insulin requirements
Hyperinsulinemia	Can enhance ovarian androgen production
Reduced SHBG	Increases biologically available androgen
Androgen excess	Contributes to follicular dysfunction and clinical hyperandrogenism

Follicular Dysfunction

Normal ovulation requires recruitment of follicles followed by selection and maturation of a dominant follicle.

In PCOS, follicular development can become arrested before normal dominant follicle maturation and ovulation.

Follicular Arrest

Multiple follicles may begin development but fail to progress normally to the preovulatory stage.

The resulting accumulation of small antral follicles contributes to the characteristic morphology of a polycystic ovary.

Anovulation

Anovulation occurs when an oocyte is not released during a menstrual cycle.

Persistent disruption of follicular maturation can produce chronic or recurrent anovulation in PCOS.

Oligo-Ovulation

Some individuals ovulate intermittently rather than being completely anovulatory.

This reduced frequency of ovulation is termed oligo-ovulation.

Menstrual Irregularity

Ovulatory dysfunction can produce irregular menstrual cycles.

Patterns may include oligomenorrhea, amenorrhea, or irregular uterine bleeding.

Polycystic Ovarian Morphology

The term polycystic ovarian morphology describes a characteristic ovarian appearance identified using appropriate imaging criteria.

The structures commonly described as cysts are predominantly small follicles rather than true pathological cysts.

Ovarian Appearance

Polycystic ovaries may contain an increased number of small antral follicles and may have increased ovarian volume.

The precise imaging thresholds used to define polycystic ovarian morphology depend on ultrasound technology and the diagnostic criteria being applied.

Peripheral Follicular Distribution

Small follicles may be arranged predominantly toward the periphery of the ovarian cortex in some polycystic ovaries.

This can produce the traditionally described peripheral follicular pattern, although this appearance is not required for diagnosis.

Ovarian Stroma

Some polycystic ovaries demonstrate increased stromal volume and enhanced stromal echogenicity on ultrasound.

The ovarian stroma contains steroidogenic tissue that contributes to ovarian endocrine function.

PCOS Is Not Defined by Ovarian Cysts Alone

The name of the syndrome can be misleading because ovarian cysts are neither necessary nor sufficient for the diagnosis.

A person can have PCOS without meeting imaging criteria for polycystic ovarian morphology, while polycystic ovarian morphology can occur in individuals who do not have PCOS.

Clinical Hyperandrogenism

Androgen excess can affect hair follicles, sebaceous glands, and other androgen-sensitive tissues.

Clinical manifestations can include hirsutism, acne, and androgen-related scalp hair thinning.

Hirsutism

Hirsutism refers to excessive terminal hair growth in androgen-dependent areas in women.

Commonly affected areas include the face, upper lip, chin, chest, abdomen, and back.

Acne

Androgens stimulate sebaceous gland activity and can contribute to acne.

Acne alone is not specific for PCOS but can occur as part of clinical hyperandrogenism.

Androgen-Related Scalp Hair Loss

Androgen excess can contribute to progressive thinning of scalp hair in susceptible individuals.

The distribution differs from the terminal hair growth associated with hirsutism.

Reproductive Manifestations

Ovulatory dysfunction can interfere with predictable menstrual cycling and fertility.

The severity varies substantially, and some individuals with PCOS continue to ovulate intermittently.

Infertility

PCOS is an important cause of anovulatory infertility.

Failure to consistently release an oocyte reduces the probability of conception during affected cycles.

Corpus Luteum Formation

Normal ovulation is followed by transformation of the ruptured follicle into the corpus luteum.

When ovulation does not occur, normal cyclic corpus luteum formation and progesterone secretion are also absent.

Progesterone Exposure

During normal ovulatory cycles, the corpus luteum produces progesterone during the luteal phase.

Chronic anovulation reduces cyclic progesterone exposure while estrogenic stimulation of the endometrium can continue.

Endometrial Effects

Prolonged exposure of the endometrium to estrogen without regular progesterone opposition can promote excessive endometrial proliferation.

This is an important consequence of chronic anovulation.

Endometrial Hyperplasia

Persistent unopposed estrogenic stimulation can increase the risk of endometrial hyperplasia.

Some forms of endometrial hyperplasia can progress toward endometrial carcinoma.

Metabolic Features

PCOS frequently has important metabolic manifestations in addition to its reproductive features.

Insulin resistance is particularly important because it can contribute both to androgen excess and to abnormalities of glucose metabolism.

Impaired Glucose Regulation

Insulin resistance increases the demand placed on pancreatic beta cells.

When compensatory insulin secretion becomes inadequate, impaired glucose tolerance or type 2 diabetes mellitus can develop.

Type 2 Diabetes Mellitus

Individuals with PCOS have an increased risk of developing type 2 diabetes mellitus, particularly when additional metabolic risk factors are present.

This association reflects the important role of insulin resistance in the syndrome.

Dyslipidemia

Abnormal lipid profiles can occur in PCOS.

The specific pattern varies but can include elevated triglycerides, reduced high-density lipoprotein cholesterol, or other atherogenic lipid abnormalities.

Obesity and PCOS

PCOS can occur at any body size and obesity is not required for diagnosis.

However, excess adiposity can worsen insulin resistance and amplify metabolic and reproductive abnormalities in susceptible individuals.

Visceral Adiposity

Accumulation of visceral adipose tissue is particularly associated with metabolic insulin resistance.

Adipose tissue also functions as an endocrine organ and releases signaling molecules that influence metabolism and inflammation.

Acanthosis Nigricans

Acanthosis nigricans is characterized by hyperpigmented, thickened, velvety skin, commonly involving intertriginous regions such as the posterior neck and axillae.

It can occur in association with substantial insulin resistance and hyperinsulinemia.

Major Features of PCOS

Feature	Underlying Mechanism
Hyperandrogenism	Increased androgen production and altered androgen availability
Irregular menstruation	Oligo-ovulation or anovulation
Polycystic ovarian morphology	Accumulation of multiple small developing follicles
Hirsutism	Androgen action on susceptible hair follicles
Infertility	Reduced or absent ovulation
Insulin resistance	Reduced metabolic responsiveness to insulin
Acanthosis nigricans	Can reflect hyperinsulinemia and insulin resistance

Diagnosis

PCOS is a syndrome rather than a disorder diagnosed by a single laboratory test.

Diagnosis requires assessment of reproductive, endocrine, and sometimes ovarian morphological features while excluding other disorders that can produce similar manifestations.

Rotterdam Criteria

A widely used diagnostic framework is based on the presence of at least two of three major features after exclusion of relevant alternative causes:

• Ovulatory dysfunction
• Clinical or biochemical hyperandrogenism
• Polycystic ovarian morphology

The precise application of diagnostic criteria varies with age, clinical circumstances, and current professional guidance.

Ovulatory Dysfunction

Menstrual history provides important information about ovulatory function.

Persistently long, irregular, or absent menstrual cycles can indicate oligo-ovulation or anovulation.

Biochemical Hyperandrogenism

Laboratory evaluation can assess circulating androgen concentrations when biochemical hyperandrogenism is suspected.

Interpretation requires appropriate assays and consideration of factors affecting hormone-binding proteins.

Ultrasound

Pelvic ultrasound can be used to evaluate ovarian morphology when imaging is clinically appropriate.

Ultrasound can assess follicle number, ovarian volume, and other structural features.

Transvaginal Ultrasound

In appropriate patients, transvaginal ultrasound generally provides detailed visualization of ovarian anatomy and small antral follicles.

The applicability of this approach depends on age and individual clinical circumstances.

Exclusion of Other Disorders

Several endocrine disorders can produce menstrual abnormalities, androgen excess, or both and may need to be excluded before PCOS is diagnosed.

Depending on the presentation, evaluation may consider:

• Thyroid dysfunction
• Hyperprolactinemia
• Nonclassic congenital adrenal hyperplasia
• Cushing syndrome
• Androgen-secreting ovarian or adrenal tumors
• Other causes of ovulatory dysfunction

Thyroid Function

Thyroid disorders can disrupt menstrual cyclicity and reproductive function.

Assessment of thyroid function can therefore be appropriate when evaluating menstrual irregularity suggestive of PCOS.

Prolactin

Hyperprolactinemia can suppress normal hypothalamic-pituitary-gonadal function and produce menstrual disturbances.

It represents an important alternative endocrine cause of ovulatory dysfunction.

Nonclassic Congenital Adrenal Hyperplasia

Nonclassic congenital adrenal hyperplasia can cause androgen excess and menstrual irregularity that resemble PCOS.

Assessment of adrenal steroid precursors can help identify this disorder when clinically indicated.

Androgen-Secreting Tumors

Ovarian or adrenal tumors can occasionally produce substantial quantities of androgens.

Rapidly progressive or severe virilization raises concern for causes of androgen excess other than typical PCOS and requires appropriate investigation.

Virilization

Marked virilization is not a typical manifestation of uncomplicated PCOS.

Features such as substantial voice deepening, clitoromegaly, rapidly progressive hirsutism, or major increases in muscle mass can indicate more severe androgen excess and warrant evaluation for alternative causes.

LH and FSH Testing

Some individuals with PCOS demonstrate relatively increased LH secretion compared with FSH.

However, an elevated LH-to-FSH ratio is neither necessary nor sufficient for diagnosis and should not be considered a defining diagnostic test.

Anti-Müllerian Hormone

Anti-Müllerian hormone (AMH) is produced by granulosa cells of developing ovarian follicles and is often elevated in PCOS because of the increased population of small follicles.

Its diagnostic use depends on age, assay characteristics, and the specific diagnostic framework being applied.

PCOS Phenotypes

Because diagnostic features occur in different combinations, PCOS can present with different phenotypes.

Some individuals demonstrate all major features, while others may have hyperandrogenism and ovulatory dysfunction without polycystic ovarian morphology, or other qualifying combinations.

PCOS and Fertility

PCOS can reduce fertility primarily through inconsistent or absent ovulation.

However, the presence of PCOS does not imply permanent infertility. Ovulation may occur spontaneously in some cycles, and treatment can often restore or induce ovulation when pregnancy is desired.

Treatment Principles

Management of PCOS depends on the individual's manifestations and goals.

Treatment may address menstrual regulation, hyperandrogenism, fertility, insulin resistance, metabolic risk factors, or combinations of these problems.

Lifestyle and Metabolic Management

For individuals with relevant metabolic risk factors, nutrition, physical activity, sleep, and weight management can influence insulin sensitivity and overall metabolic health.

Changes that improve insulin sensitivity can also improve reproductive and endocrine abnormalities in some patients.

Menstrual Regulation

Hormonal therapy can be used in appropriate patients to regulate menstrual bleeding and provide predictable progestogen exposure to the endometrium.

This is particularly important when chronic anovulation results in prolonged periods without progesterone exposure.

Combined Hormonal Contraceptives

Combined hormonal contraceptives are commonly used when pregnancy is not desired and treatment of menstrual irregularity or hyperandrogenic manifestations is needed.

They suppress ovarian androgen production and can increase hepatic SHBG production, thereby reducing biologically available androgen.

Progestogen Therapy

Periodic progestogen exposure can induce withdrawal bleeding and protect the endometrium from prolonged unopposed estrogenic stimulation in selected patients with chronic anovulation.

Metformin

Metformin improves insulin sensitivity and reduces hepatic glucose production.

It can be useful for selected metabolic abnormalities associated with PCOS and can improve menstrual cyclicity in some individuals.

Ovulation Induction

When infertility results from anovulation, pharmacological induction of ovulation can be considered.

Treatment aims to promote development of a mature follicle followed by ovulation while minimizing risks associated with excessive ovarian stimulation.

Letrozole

Letrozole is an aromatase inhibitor used for ovulation induction in anovulatory infertility associated with PCOS.

Temporary reduction of estrogen synthesis alters hypothalamic-pituitary feedback and promotes gonadotropin stimulation of follicular development.

Antiandrogen Therapy

Antiandrogen medications can reduce androgen-mediated manifestations such as hirsutism in appropriately selected patients.

Because some antiandrogens can adversely affect fetal development, reliable contraception is important when these medications are used in individuals who could become pregnant.

Long-Term Endometrial Considerations

Chronic anovulation can expose the endometrium to prolonged estrogenic stimulation without regular progesterone-mediated differentiation and shedding.

Appropriate management of prolonged menstrual irregularity therefore has significance beyond cycle predictability.

Long-Term Metabolic Considerations

Because insulin resistance and abnormal glucose regulation are common in PCOS, long-term care can include assessment of metabolic risk factors.

These can include glucose regulation, blood pressure, lipid abnormalities, body composition, and other cardiovascular risk factors.

PCOS Versus Normal Polycystic Ovarian Morphology

Feature	PCOS	Isolated Polycystic Ovarian Morphology
Endocrine syndrome	Present	Absent by morphology alone
Hyperandrogenism	May be present	Not required
Ovulatory dysfunction	May be present	Not required
Polycystic ovarian morphology	May be present	Present
Diagnosis of PCOS	Depends on diagnostic criteria and exclusion of alternatives	Cannot be made from ovarian appearance alone

Key Features of PCOS

Feature	Key Point
Primary organs involved	Ovaries with broader hypothalamic, pituitary and metabolic involvement
Major reproductive abnormality	Oligo-ovulation or anovulation
Major endocrine abnormality	Hyperandrogenism in many affected individuals
Ovarian morphology	Increased population of small developing follicles in many patients
Important metabolic association	Insulin resistance
Effect of hyperinsulinemia	Can increase ovarian androgen production and reduce SHBG
Menstrual effect	Irregular or absent ovulation and menstrual cycles
Fertility effect	Can cause anovulatory infertility
Endometrial concern	Prolonged unopposed estrogen exposure during chronic anovulation
Metabolic concern	Increased risk of impaired glucose regulation and type 2 diabetes

Anatomical and Physiological Importance

Polycystic ovary syndrome demonstrates the close relationship between ovarian anatomy and endocrine physiology. Normal follicular development requires coordinated signaling among the hypothalamus, anterior pituitary, ovarian theca cells, granulosa cells, and developing follicles. Disturbance of these relationships can prevent normal dominant follicle development and ovulation.

The characteristic ovarian appearance reflects this altered follicular physiology. Rather than representing an ovary filled with conventional pathological cysts, many polycystic ovaries contain an increased number of small follicles whose development has not progressed normally to ovulation. This explains why the anatomical term can be misleading when separated from the underlying reproductive endocrinology.

PCOS also demonstrates how metabolic and reproductive endocrine pathways interact. Insulin resistance can produce compensatory hyperinsulinemia, which can enhance ovarian androgen production and decrease hepatic SHBG production. Increased androgen availability can further disturb normal follicular development and contribute to hirsutism, acne, and other manifestations.

The syndrome therefore cannot be understood as an isolated structural disorder of the ovaries. It represents a broader endocrine condition involving ovarian steroidogenesis, gonadotropin regulation, follicular maturation, insulin signaling, and target tissues throughout the body.